The European Association of Nuclear Medicine announced the 2026 EANM Young Scientist Network Award, funded by Advanced Accelerator Applications (a Novartis company), to support alpha radioligand therapy (α‑RLT) research for prostate cancer. The award targets early‑career investigators and aims to catalyze translational projects in a field seeing renewed clinical interest. By directing resources toward α‑RLT, EANM and its industry partner expect to accelerate preclinical validation and clinical trial readiness for alpha‑emitting radiopharmaceuticals, which offer high linear energy transfer and promise for targeting micrometastatic disease.